Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2016 - 2025)

Historic Research & Development for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $86.3 million.

  • Viridian Therapeutics, Inc.\DE's Research & Development rose 2473.03% to $86.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.7 million, marking a year-over-year increase of 5703.14%. This contributed to the annual value of $238.3 million for FY2024, which is 4912.78% up from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Research & Development stood at $86.3 million, which was up 2473.03% from $86.6 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Research & Development peaked at $86.6 million during Q2 2025, and registered a low of $8.1 million during Q3 2021.
  • Moreover, its 5-year median value for Research & Development was $39.3 million (2022), whereas its average is $42.4 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Research & Development soared by 22755.47% in 2021, and later plummeted by 1930.63% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Research & Development (Quarter) stood at $22.4 million in 2021, then surged by 75.57% to $39.3 million in 2022, then fell by 1.93% to $38.6 million in 2023, then surged by 86.63% to $72.0 million in 2024, then rose by 19.87% to $86.3 million in 2025.
  • Its Research & Development was $86.3 million in Q3 2025, compared to $86.6 million in Q2 2025 and $76.8 million in Q1 2025.